US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Nuvectis Pharma, Inc.

< Previous 1 2 Next >
News headline image
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma to Present at the 36th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
News headline image
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Tickers NVCT
< Previous 1 2 Next >